1. Home
  2. CTRM vs ITRM Comparison

CTRM vs ITRM Comparison

Compare CTRM & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.10

Market Cap

21.2M

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.17

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
ITRM
Founded
2016
2015
Country
Cyprus
Ireland
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
24.3M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
CTRM
ITRM
Price
$2.10
$0.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
54.9K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$0.14
52 Week High
$2.67
$1.49

Technical Indicators

Market Signals
Indicator
CTRM
ITRM
Relative Strength Index (RSI) 43.04 36.88
Support Level $2.07 $0.14
Resistance Level $2.20 $0.39
Average True Range (ATR) 0.11 0.03
MACD -0.01 -0.00
Stochastic Oscillator 17.31 21.61

Price Performance

Historical Comparison
CTRM
ITRM

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: